Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from AstraZeneca

Shares surge in drug discovery company after $402m AstraZeneca deal announced

Shares in C4X Discovery Holdings plc have jumped since the deal was announced

Birmingham Post

AstraZeneca’s CEO on Covid: ‘We Just Have to Adjust to it’

AstraZeneca’s Chief Executive Officer, Sir Pascal Soriot, told Asharq Al-Awsat in an interview that Covid-19 is not over “and we just have to adjust to it like we live with the flu.” “Most people who get it basically get sick for a few days and do not need to be…

Asharq Al-Awsat

Kellogg Makes Morningstar List of Undervalued Stocks

The S&P 500 has slid this year, but some stocks have gained, and some of these winners are undervalued, Morningstar says.

The Street

From analysis to the latest developments in health,
read the most diverse news in one place.

AstraZeneca Makes A Break For A Buy Point On Massive Third-Quarter Growth

AstraZeneca leaned on cancer drugs in the third-quarter, leading to double-digit sales growth, a strong beat and a jump for AZN stock.

Investors Business Daily

Troubled FTX Faces SEC Probe And 'Urgently Needs' $8B To Avoid Bankruptcy, NIO Posts Wider Q3 Loss, AstraZeneca Ditches US Application Submission For COVID-19 Shot: Top Stories Thursday, Nov. 11

Bloomberg

Benzinga

Dow Jones Surges 900 Points On Cool Inflation Data; Treasury Yields Dive

The Dow Jones Industrial Average surged 900 points Thursday on cool inflation data, with the consumer price index (CPI) coming in lower than expected.

Investors Business Daily

AstraZeneca drops plans for Covid jab approval in US

The drugs giant will instead focus its Covid-19 vaccine efforts elsewhere globally and for its use as a booster.

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

AstraZeneca returns to profit on higher drugs revenue

London (AFP) - British pharmaceuticals giant AstraZeneca on Thursday announced a return to third-quarter profit on increased revenue from sales of its drugs.

AFP

Expert warns of winter Covid surge

A Chulalongkorn University virologist has warned about a potential surge in Covid-19 cases during the cold season that will likely peak in January.

Bangkok Post

AstraZeneca looks fighting fit despite the ills of the UK science sector

Brexit fallout plus funding fears mean an uncertain prognosis, but the firm will report good news this week

The Guardian - UK

EU approves preventative treatment for common infant virus

Paris (AFP) - The European Union has approved a preventative treatment for the very common virus that causes the chest infection bronchiolitis in infants, the companies that developed the drug said Friday.

AFP

Tesla Shifts China Factory Workers To US Plant, Complete European Approval For AstraZeneca's COVID-19 Shot, Tesla Eyes Cybertruck Commercialization Next Year: Top Stories Tuesday, Nov. 1

Bloomberg Tesla Migrates Shanghai Factory Workers To Boost US Plant Production

Benzinga

Study confirms AstraZeneca jab's higher risk of very rare clot

Paris (AFP) - AstraZeneca's Covid vaccine has been linked to a 30-percent higher risk of getting a very rare blood clotting condition compared to the Pfizer jab, a large international study said Thursday.

AFP

Intel's Self-Driving Tech Firm Raises Over $800M In IPO, Alphabet Misses Q3 Earnings Expectations, Lyft Cuts Price For Monthly Subscription Plan: Top Stories Wednesday, Oct. 26

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Asharq Al-Awsat

High Hopes for Nasal Covid Vaccines despite 'Disappointing' Trial

Nasal vaccines could still be a powerful future weapon in the fight against Covid-19 despite "disappointing" recent trial results for an AstraZeneca spray, experts say. By entering the body the same way as the virus, nasal vaccines aim to build immunity in the mucous membrane that lines the nose and…

AFP

High hopes for nasal Covid vaccines despite 'disappointing' trial

Paris (AFP) - Nasal vaccines could still be a powerful future weapon in the fight against Covid-19 despite "disappointing" recent trial results for an AstraZeneca spray, experts say.

ABC News

What vaccine can you get, based on your age? These are the recommended COVID-19 vaccines for each age group

More than 14.2 million Australians over the age of 16 have now received three or more doses. So which are the best vaccines for each age group?

The Independent UK

Super-gene that generates higher antibodies against Covid discovered

People carrying the super-gene recorded higher antibody responses against the Covid-19 vaccines 28 days following the first dose

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Japan reopening: What are the current travel rules and do I need a Covid test?

The country reopened to individual tourists on 11 October

The Independent UK

Hillary Clinton giving girls Instagram access to ‘stand up for gender equality’

The former US presidential hopeful was supporting the United Nations’ International Day Of The Girl.

The Guardian - UK

Covid: hopes for Oxford nasal vaccine dealt blow after poor trial results

Scientists ditch plans to develop nasal spray version of Oxford/AstraZeneca vaccine in its current form

The Guardian - UK

Ex-vaccine head accuses Hancock of ‘Jekyll and Hyde’ behaviour in meeting

Dame Kate Bingham says former health secretary aggressively questioned her competence in front of cabinet

The Independent UK

Trainee solicitor died from ‘rare complication’ of AstraZeneca Covid-19 jab

Oli Akram Hoque, 26, developed a “vaccine induced” cerebral venous sinuous thrombosis after his first dose of AstraZeneca’s Covid-19 vaccine.

The Conversation

Pollen does more than make you sneeze. It can cause thunderstorm asthma, even if you're not asthmatic

Climate change has caused melting icebergs, flooding, and landslides. It can also bring about an increase in pollen levels, prolong the duration of pollen season, and cause more pollen-related health problems.

Benzinga

Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share.

1 … 8 9 10 11

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.